An interventional study of Slump Neural Slider Technique and Slump Neural Tensioner Technique in Dynamic Balance in Asymptomatic Young Adults, sponsored by Gulf Medical University. Completed at 1 site in United Arab Emirates. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Gulf Medical University · Not applicable, Interventional, and Basic science
The goal of this interventional study is to learn if slump neural tensioner and slump neural slider techniques can immediately improve dynamic balance in asymptomatic healthy young adults aged 18-25 years. The main questions it aims to answer are:
Does the slump neural tensioner technique produce greater immediate improvement in dynamic balance compared to the slump neural slider technique? Do both techniques improve Y Balance Test scores immediately after a single session of treatment?
Researchers will compare the slump neural tensioner group to the slump neural slider group to see if one technique produces a greater immediate effect on dynamic balance.
Participants will:
Be randomly assigned to receive either the slump neural slider or the slump neural tensioner technique in a single session Perform 10 repetitions of their assigned technique for 3 sets in the slump sitting position Have their dynamic balance measured using the Lower Quarter Y Balance Test before and immediately after the intervention Complete the entire session in approximately 30-45 minutes in one visit only
BACKGROUND Dynamic balance is a fundamental sensorimotor function required for safe and efficient movement during daily activities, sports, and rehabilitation. It depends on the continuous integration of proprioceptive, vestibular, and visual inputs with appropriate neuromuscular responses. Restrictions in neural tissue mobility - even in asymptomatic individuals - may impair afferent proprioceptive signaling from mechanoreceptors distributed along the peripheral neural pathway, potentially degrading neuromuscular coordination and dynamic balance performance.
Neural mobilization (NM) is a movement-based physiotherapy intervention designed to restore normal neural tissue mechanics and physiology. It comprises two primary techniques: the neural slider, which promotes nerve excursion through alternating opposite-direction joint movements with minimal neural strain; and the neural tensioner, which applies controlled mechanical loading through simultaneous same-direction joint movements to improve the viscoelastic properties of neural tissues. Both techniques are performed in the slump sitting position - a standardized posture that effectively loads the posterior neuromeningeal tract and sciatic nerve - making it optimal for lower limb neurodynamic interventions.
While existing evidence confirms that both techniques improve hamstring flexibility and reduce neural mechanosensitivity, their comparative immediate effects on dynamic balance in asymptomatic young adults remain unclear. Most prior studies have focused on symptomatic populations, making it difficult to isolate the pure neurodynamic contribution to balance from the confounding effects of pain relief. The present study was designed to address this gap.
STUDY DESIGN This is a two-arm parallel-group randomized controlled trial. Participants are randomly allocated in a 1:1 ratio to one of two intervention groups using a computer-generated randomization sequence prepared by an independent researcher not involved in data collection. Allocation concealment is maintained using sequentially numbered, sealed opaque envelopes opened immediately prior to the intervention session.
SETTING The study is conducted at the Physiotherapy Laboratory, College of Health Sciences, Gulf Medical University, Ajman, United Arab Emirates. All assessments and interventions are performed in the same standardized laboratory environment to minimize environmental confounding.
PARTICIPANTS One hundred asymptomatic young adults aged 18-25 years are recruited from Gulf Medical University and the surrounding community using convenience sampling. Eligibility is confirmed through clinical screening, the Nordic Musculoskeletal Questionnaire (NMQ), and physical assessment prior to enrollment.
Inclusion Criteria:
Age 18-25 years Male or female Healthy with no current musculoskeletal pain or neurological symptoms Able to assume and maintain the slump sitting position Willing to provide written informed consent
Exclusion Criteria:
Diagnosed neurological disorders Musculoskeletal injury or surgery within the past 6 months Vestibular dysfunction or balance disorders Lower limb deformity or congenital abnormalities Active musculoskeletal pain (NRS > 0/10) Any contraindication to neural mobilization
BASELINE ASSESSMENTS
Prior to randomization, all participants undergo the following standardized assessments performed by a trained physiotherapist:
Demographic and anthropometric data: age, gender, height, weight, body mass index (BMI) Nordic Musculoskeletal Questionnaire (NMQ) for musculoskeletal symptom screening International Physical Activity Questionnaire - Short Form (IPAQ-SF) for physical activity level classification Leg length measurement: anterior superior iliac spine (ASIS) to medial malleolus using a measuring tape Foot length measurement: heel to longest toe using a standardized measuring scale Hamstring length: Active Knee Extension Test (90-90 test) using a universal goniometer (ICC > 0.90) Knee range of motion: universal goniometer Ankle dorsiflexion range of motion: universal goniometer
Primary Outcome - Lower Quarter Y Balance Test (YBT-LQ):
Dynamic balance is assessed using the Lower Quarter Y Balance Test in three reach directions: anterior (ANT), posteromedial (PM), and posterolateral (PL). Participants stand on the test limb on a central platform and reach maximally with the contralateral limb in each direction. Three practice trials are performed to minimize learning effects, followed by three recorded trials per direction. Reach distances are measured in centimetres, normalized to leg length, and averaged across three trials. A composite score is calculated as the mean of the three normalized reach distances multiplied by 100. The YBT-LQ demonstrates high reliability (ICC = 0.85-0.99) and predictive validity for lower extremity injury risk.
INTERVENTIONS Both interventions are administered by the same trained physiotherapist following a standardized written protocol. All participants are positioned in the slump sitting posture: thoracic and lumbar spine in full flexion, hands clasped behind the back, hips flexed to 90 degrees, knees flexed to approximately 90 degrees, and ankles in neutral position.
Group A - Slump Neural Slider Technique:
The participant actively performs cervical spine extension combined with knee extension and ankle dorsiflexion, followed by cervical spine flexion combined with knee flexion and ankle relaxation. This alternating movement promotes bidirectional neural excursion along the posterior kinetic chain with minimal increase in neural strain. The end position is held for 2 seconds before returning to the starting position. The movement is performed slowly and in a controlled manner at approximately 4 seconds per repetition. The technique is administered for 10 repetitions per set, 3 sets, with 30-second rest intervals between sets. Total intervention time is approximately 3-4 minutes. The intervention is stopped immediately if the participant reports pain greater than 3/10, numbness, tingling, dizziness, or cramping.
Group B - Slump Neural Tensioner Technique:
The participant maintains the cervical spine in sustained flexion while simultaneously performing active knee extension and ankle dorsiflexion, progressively increasing mechanical loading along the entire posterior neuromeningeal pathway. The end position is held for 2-3 seconds before returning to the starting position. Movements are slow and controlled at approximately 4-5 seconds per repetition. The technique is administered for 10 repetitions per set, 3 sets, with 30-second rest intervals between sets. Total intervention time is approximately 3-4 minutes. The intervention is stopped immediately if the participant reports pain greater than 3/10, numbness, tingling, dizziness, or excessive neural discomfort.
POST-INTERVENTION ASSESSMENT Immediately following the completion of the assigned intervention, dynamic balance is reassessed using the Lower Quarter Y Balance Test following the identical standardized procedure used at baseline. Reach distances in the anterior, posteromedial, and posterolateral directions are recorded as post-intervention outcome values.
SAMPLE SIZE The sample size was calculated based on the two-sample independent t-test formula for comparison of two independent groups. Assuming a two-tailed alpha of 0.05, 80% statistical power, a clinically meaningful between-group difference of 5 points in the YBT composite score, and a pooled standard deviation of approximately 8 points derived from pilot data and prior literature, the required sample size is approximately 44 participants per group. This was increased to 50 per group (total n = 100) to account for a 10-12% dropout rate commonly observed in similar single-session intervention studies, ensuring adequate statistical power for robust inference.
STATISTICAL ANALYSIS PLAN
All data are entered and analyzed using IBM SPSS Statistics software (Version 28). The following analytical approach is employed:
Descriptive Statistics: Mean and standard deviation for continuous variables; frequency and percentage for categorical variables. Used to summarize baseline demographic and anthropometric characteristics of both groups.
Normality Testing: Shapiro-Wilk test applied to all continuous outcome variables prior to inferential analysis.
Within-Group Analysis: Paired samples t-test used to compare pre- and post-intervention YBT reach distances (ANT, PM, PL, and composite score) within each group separately.
Between-Group Analysis: Independent samples t-test used to compare the magnitude of change (post minus pre) in YBT scores between Group A (Neural Slider) and Group B (Neural Tensioner).
Effect Size: Cohen's d calculated for all significant comparisons to quantify the practical significance of observed differences.
Side-to-Side Asymmetry: Paired t-test used to evaluate limb asymmetry in YBT reach distances before and after the intervention within each group.
Level of Significance: p \< 0.05 is considered statistically significant for all analyses.
PLAN FOR MISSING DATA Given the single-session design of this study, missing data are not anticipated. However, should any participant be unable to complete the post-intervention YBT assessment due to discomfort or withdrawal, their data will be excluded from the analysis and documented as a protocol deviation. No imputation methods will be applied. All withdrawals and reasons for missing data will be reported transparently in the final manuscript.
DATA MANAGEMENT AND QUALITY ASSURANCE All data are recorded on pre-designed, standardized paper-based data collection forms at the time of assessment. Data are subsequently entered into password-protected electronic spreadsheets by the principal investigator. A second team member independently verifies 100% of entered data against source documents to identify and correct transcription errors. Both hard copy and electronic copies of all data are stored securely at Gulf Medical University for a minimum of three years following study completion, accessible only to the authorized research team. No personal identifiers are included in the analysis dataset; participants are identified by unique numeric codes only.
ETHICAL CONSIDERATIONS The study has received ethical approval from the Gulf Medical University Institutional Review Board (GMU-IRB). All participants provide written informed consent prior to enrollment. Participation is entirely voluntary and participants may withdraw at any time without consequence. Confidentiality is maintained throughout by replacing personal identifiers with participant codes in all records and publications.
Gulf Medical University is the lead sponsor of 43 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 18 and 25 years
Exclusion Criteria:
Diagnosed neurological disorders (e.g., peripheral neuropathy, multiple sclerosis) (39).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the slump neural slider technique in slump sitting position. Cervical extension combined with knee extension and ankle dorsiflexion, then cervical flexion with knee flexion. 10 repetitions per set, 3 sets, 30 second rest between sets.
Other: Slump Neural Slider Technique
Participants receive the slump neural tensioner technique in slump sitting position. Sustained cervical flexion with simultaneous knee extension and ankle dorsiflexion. 10 repetitions per set, 3 sets, 30 second rest between sets.
Other: Slump Neural Tensioner Technique
Performed in slump sitting with thoracic and lumbar flexion, hips at 90 degrees. Cervical extension with knee extension and ankle dorsiflexion, then return. End position held 2 seconds. 10 repetitions, 3 sets, 30 second rest. Total 3 to 4 minutes.
Performed in slump sitting with thoracic and lumbar flexion, hips at 90 degrees. Sustained cervical flexion with simultaneous knee extension and ankle dorsiflexion. End position held 2 to 3 seconds. 10 repetitions, 3 sets, 30 second rest. Total 3 to 4 minutes.
Change in normalized Y-Balance Test composite scores from baseline to immediately and 20 min after intervention
Dynamic balance was assessed using the Lower Quarter Y-Balance Test for the right and left lower limbs. For each limb, the composite score was calculated as \[(anterior + posteromedial + posterolateral reach distances)/(3 × limb length)\] × 100 and expressed as percentage of limb length. Changes from baseline to immediately after intervention were compared between the slump neural slider and slump neural tensioner groups. Higher scores indicate better dynamic balance.
Time frame: Baseline and immediately after a single intervention session.
Change in hamstring flexibility measured using the Active Knee Extension test
Hamstring flexibility was assessed in the right and left lower limbs using the Active Knee Extension test. Knee extension range was recorded in degrees. Changes from baseline to immediately after intervention were assessed within each group.
Time frame: Baseline and immediately after a single intervention session.
Change in ankle dorsiflexion range of motion
Ankle dorsiflexion range of motion was measured in degrees for the right and left lower limbs. Changes from baseline to immediately after intervention were assessed within each group.
Time frame: Baseline and immediately after a single intervention session.
Change in ankle plantarflexion range of motion
Ankle plantarflexion range of motion was measured in degrees for the right and left lower limbs. Changes from baseline to immediately after intervention were assessed within each group.
Time frame: Baseline and immediately after a single intervention session.
Change in knee range of motion
Knee range of motion was measured in degrees for the right and left lower limbs. Changes from baseline to immediately after intervention were assessed within each group.
Time frame: Baseline and immediately after a single intervention session.
Plan to share: No — "Individual participant data will not be shared. Study findings will be reported in aggregate form in publications and presentations
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Aug 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gulf Medical University